The Very Lazy Evodiamine's Solution To Be Successful

An additional one-way sensitivity analysis was performed where clinical events were varied from the lower and upper bounds of their 95% confidence intervals. Results Base-case analysis In the base-case analysis, while the estimated lifetime mean number of thrombotic find more events per patient was similar between treatment groups, the mean number of hemorrhagic events was lower for edoxaban relative to rivaroxaban (Table 5). These findings resulted in a numerically higher mean number of QALYs for edoxaban (7.299 versus 7.238), and lower mean total health care cost for edoxaban than rivaroxaban ($45,358 versus $49,472 per patient) (Table 5). Therefore, edoxaban was economically dominant over rivaroxaban in the base-case analysis. Across both therapies, about 24% of total health care cost was attributable to acute events, 31% was attributable to time spent in chronic health states, and the remaining 45% of total costs came from the OAC drugs themselves. Table 5 Analysis results Sensitivity analyses In one-way sensitivity analyses, when the acquisition cost of edoxaban was increased by 13.5% to the same level as rivaroxaban, at $10.49 per day, edoxaban remained dominant over rivaroxaban, with cost savings of $1,382 per patient (mean per patient cost of $48,090 edoxaban versus $49,472 rivaroxaban) and higher QALYs (7.299 versus 7.238) (Table 6). The cost-effectiveness of edoxaban relative to rivaroxaban was not sensitive to age. Edoxaban remained the economically dominant therapy versus rivaroxaban when cost parameters were varied ��10% from their base values and utilities were varied ��25% from their base values. Although Evodiamine not reported in Table 6, edoxaban also remained the economically dominant therapy versus rivaroxaban when risks of clinical events were varied from the lower and upper bounds of their 95% confidence intervals. Table 6 Results of one-way sensitivity analyses In the Monte Carlo probabilistic sensitivity analysis with 10,000 model iterations, in which all model parameters were randomly sampled from their distributions, edoxaban yielded an ICER Epigenetics Compound Library cost from a US health-plan perspective. Our analysis found that edoxaban was associated with greater quality-adjusted life expectancy at lower total health care costs than rivaroxaban. This finding of economic dominance was robust under a series of one-way sensitivity analysis where event-treatment cost and health state-utility estimates were varied. The cost-effectiveness of edoxaban relative to rivaroxaban for stroke prevention was further supported by probabilistic sensitivity analysis where all model parameters were randomly sampled from their distribution, and ICER estimates fell below $50,000 per QALY gained in 88.